Combination of rhG-CSF With Decitabine Prophylaxis Reduces Relapse in Patients With High-Risk MRD-Negative AML After HSCT
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Effect of rhG-CSF Combined With Decitabine Prophylaxis on Relapse of Patients With High-Risk MRD-Negative AML After HSCT: An Open-Label, Multicenter, Randomized Controlled Trial
J. Clin. Oncol 2020 Oct 27;[EPub Ahead of Print], L Gao, Y Zhang, S Wang, P Kong, Y Su, J Hu, M Jiang, H Bai, T Lang, J Wang, L Liu, T Yang, X Huang, F Liu, S Lou, Y Liu, C Zhang, H Liu, L Gao, J Liu, L Zhu, Q Wen, T Chen, P Wang, J Rao, M Mao, C Wang, X Duan, L Luo, X Peng, K Cassady, JF Zhong, X ZhangFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.